Table 8.
Comparative vascular adverse event data for TPE in MG.
| References | Gajdos et al. (41) | Barth et al. (5) | Qureshi et al. (42) | Murthy et al. (47) | Köhler et al. (52) | Trikha et al. (65) | Rønager et al. (45) | Saeteng et al. (56) | El-Bawab et al. (64) | (1) | Guptill et al. (62) | Mandawat et al. (63) | Passero et al. (70) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Treatment context | Acute | Acute | Acute | Acute | Acute | Acute | Chronic | Peri-op | Peri-op | Mixed | Mixed | Mixed | NS |
| TPE | TPE | TPE | |||||||||||
| Comparison | TPE/ | TPE/ | TPE/ | TPE/ | TPE/ | TPE QD/ | TPE/ | TPE/ | all pts/ | TPE/ | Peripheral | TPE early/ | citrate/ |
| IVIG | IVIG | IVIG | IVIG | lA | TPE QAD | IVIG | No TPE | TPE | MG | /TPE | TPE delayed | TPE | |
| selective | central* | heparin | |||||||||||
| Timing | 15 d | 30 d | hosp. | Tx | Tx | hosp. | 16 wk | hosp. | hosp. | hosp. | Tx | hosp. | Tx |
| # Patients | 41/46 | 41/40 | 28/26 | 15/8 | 10/9 | 16/17 | 12/12 | 33/53 | 74/90 | 1,269/340 | 100/34 | 870/183 | 72/107 |
| Flow complication | - | 10/0% | - | - | - | 0/6% | - | - | 5/2% | - | - | - | 14/6% |
| Bleeding | - | - | - | - | - | 0/0% | 8/0% | 3/0% | - | - | 0/3% | - | - |
| Hemorrhage | - | - | - | - | 0/11% | - | - | - | - | - | - | - | - |
| Hematoma | - | - | - | - | 30/0% | - | - | - | - | - | 0/6% | - | - |
| Coagulopathy | 5/0% | - | 4/0% | - | - | - | - | - | 7/1% | - | - | - | - |
| Anemia | 2/0% | 0/3% | - | - | - | - | - | - | - | - | 0/9%∧ | - | - |
| Pancytopenia | - | - | - | - | 10/0% | - | - | - | - | - | - | - | - |
| Deep Vein Thrombosis | - | - | - | - | - | 13/6% | 8/0% | - | - | - | 0/12%∧ | - | - |
| Pulmonary embolism | - | - | - | - | - | - | - | - | - | - | 0/3% | - | - |
| Thrombosis (Unspecified) | 2/0% | - | - | - | - | - | - | 0/0% | - | 2/1% | 0/3% | 1/1% | - |
| Syncope | - | 5/0% | - | - | - | - | - | - | - | - | 1/0% | - | - |
| Hypotension | 5/0% | - | - | 13/0% | 20/11% | 19/18% | 17/0% | - | 11/4% | - | - | - | - |
| Hypertension | - | 0/3% | - | - | - | - | - | - | - | - | - | - | - |
| Vasospasm | - | 20/0%∧ | - | - | - | - | - | - | - | - | - | - | - |
hosp., during hospitalization; Tx, during treatment period; NS, not specified; lA, immunoadsorption; QD, daily; QAD, every other day. No significant difference observed between treatments (p ≥ 0.05) unless noted.
∧
p < 0.05 as reported by original authors or calculated using Fisher exact test;
*
peripheral venous access and central venous access;†180 day follow up.